Cargando…

Central nervous system biomarkers for antiobesity drug development()

With antiobesity agents, weight loss can emerge from an array of metabolic, cognitive and behavioural changes that translate into weight change over time. In early drug development, characterising these changes can actually be more informative than simply measuring weight loss. Biomarkers for these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ziauddeen, Hisham, Fletcher, Paul C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Ltd. ;, Distributed by Virgin Mailing and Distribution 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858811/ https://www.ncbi.nlm.nih.gov/pubmed/23993917 http://dx.doi.org/10.1016/j.drudis.2013.08.015

Ejemplares similares

Lorcaserin: A novel antiobesity drug
por: Brashier, Dick B. S., et al.
Publicado: (2014)

Predictors of weight loss and maintenance in patients treated with antiobesity drugs
por: Guaraldi, Federica, et al.
Publicado: (2011)

Sugar addiction: the state of the science
por: Westwater, Margaret L., et al.
Publicado: (2016)

Drugs in Central Nervous System Disorders
por: Perry, Bruce D.
Publicado: (1985)

Nanomaterials for Drug Delivery to the Central Nervous System
por: Teleanu, Daniel Mihai, et al.
Publicado: (2019)

Biomarkers in Rare Demyelinating Disease of the Central Nervous System
por: Boziki, Marina, et al.
Publicado: (2020)

Plants' Metabolites as Potential Antiobesity Agents
por: Gooda Sahib, Najla, et al.
Publicado: (2012)

Current Understanding of Antiobesity Property of Capsaicin
por: Narang, Nithida, et al.
Publicado: (2017)

Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity
por: Mital, Shweta, et al.
Publicado: (2023)

Pathogen-inspired drug delivery to the central nervous system
por: McCall, Rebecca L, et al.
Publicado: (2014)

Updates on Antiobesity Effect of Garcinia Origin (−)-HCA
por: Chuah, Li Oon, et al.
Publicado: (2013)

Antiobesity Effects of Anthocyanins in Preclinical and Clinical Studies
por: Azzini, Elena, et al.
Publicado: (2017)

Potassium Ion Channels in Malignant Central Nervous System Cancers
por: Boyle, Yasmin, et al.
Publicado: (2022)

Peptidylarginine deiminases and extracellular vesicles: prospective drug targets and biomarkers in central nervous system diseases and repair
por: Lange, Sigrun
Publicado: (2020)

Biomarkers of Alzheimer's Disease: From Central Nervous System to Periphery?
por: Mossello, Enrico, et al.
Publicado: (2010)

Strategies for Enhanced Drug Delivery to the Central Nervous System
por: Dwibhashyam, V. S. N. M., et al.
Publicado: (2008)

Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System
por: Crowe, Tyler P., et al.
Publicado: (2022)

Novel insights into the biomarkers and therapies for primary central nervous system lymphoma
por: Zhai, Yujia, et al.
Publicado: (2022)

Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
por: Scotto, Giulia, et al.
Publicado: (2021)

Blood Based Biomarkers of Central Nervous System Involvement in Wilson’s Disease
por: Antos, Agnieszka, et al.
Publicado: (2023)

The Use of Central Nervous System Active Drugs During Pregnancy
por: Källén, Bengt, et al.
Publicado: (2013)

Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach
por: Pavan, Barbara, et al.
Publicado: (2008)

Drug Repositioning for Refractory Benign Tumors of the Central Nervous System
por: Tamura, Ryota
Publicado: (2023)

Astrocytes: the neglected stars in the central nervous system and drug addiction
por: Chen, Wenjun, et al.
Publicado: (2022)

The importance of microglia in the development of the vasculature in the central nervous system
por: Arnold, Tom, et al.
Publicado: (2013)

Rare central nervous system lymphomas
por: Kaji, Furqaan Ahmed, et al.
Publicado: (2022)

Biomarkers in autoimmune diseases of the central nervous system
por: Zhang, Fenghe, et al.
Publicado: (2023)

Clinical and economic considerations of antiobesity treatment: a review of orlistat
por: Zohrabian, Armineh
Publicado: (2010)

Drug Penetration into the Central Nervous System: Pharmacokinetic Concepts and In Vitro Model Systems
por: Neumaier, Felix, et al.
Publicado: (2021)

Copper Ionophores as Novel Antiobesity Therapeutics
por: Meggyesy, Peter M., et al.
Publicado: (2020)

Vascularisation of the central nervous system
por: Tata, Mathew, et al.
Publicado: (2015)

Mucormycosis of the Central Nervous System
por: Chikley, Amanda, et al.
Publicado: (2019)

Developing Central Nervous System and Vulnerability to Platinum Compounds
por: Bernocchi, G., et al.
Publicado: (2011)

Pregnancy Ketonemia and Development of the Fetal Central Nervous System
por: Bronisz, Agata, et al.
Publicado: (2018)

Central Nervous System Drug Evaluation Using Positron Emission Tomography
por: Sekine, Mizuho, et al.
Publicado: (2011)

Targeted Drug Delivery to the Central Nervous System Using Extracellular Vesicles
por: Zhou, Lina, et al.
Publicado: (2022)

Glycosaminoglycans and Glycomimetics in the Central Nervous System
por: Rowlands, Dáire, et al.
Publicado: (2015)

The Olig family affects central nervous system development and disease
por: Tan, Botao, et al.
Publicado: (2014)

Retinal Electrophysiology Is a Viable Preclinical Biomarker for Drug Penetrance into the Central Nervous System
por: Charng, Jason, et al.
Publicado: (2016)

Metabolic and Epigenetics Action Mechanisms of Antiobesity Medicinal Plants and Phytochemicals
por: Saad, Bashar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hjbqlu0s5pfacck17k9mvge271